{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:23:28Z","timestamp":1790738608122,"version":"4.1.0"},"reference-count":240,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","neurologic.theclinics.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.ncl.2015.08.006","type":"journal-article","created":{"date-parts":[[2015,11,25]],"date-time":"2015-11-25T01:51:04Z","timestamp":1448416264000},"page":"133-169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Medicinal-Induced Behavior Disorders"],"prefix":"10.1016","volume":"34","author":[{"given":"Sai Krishna J.","family":"Munjampalli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra E.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ncl.2015.08.006_bib1","series-title":"Approach to diagnosis: occupational and environmental neurotoxicology","author":"Feldman","year":"1999"},{"key":"10.1016\/j.ncl.2015.08.006_bib2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1055\/s-0031-1277989","article-title":"Toxic encephalopathy","volume":"31","author":"Dobbs","year":"2011","journal-title":"Semin Neurol"},{"issue":"Suppl","key":"10.1016\/j.ncl.2015.08.006_bib3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF00543711","article-title":"CNS-related (side-)effects of beta-blockers with special reference to mechanisms of action","volume":"28","author":"Koella","year":"1985","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ncl.2015.08.006_bib4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.emc.2013.09.004","article-title":"Central nervous system toxicity","volume":"32","author":"Ruha","year":"2014","journal-title":"Emerg Med Clin North Am"},{"key":"10.1016\/j.ncl.2015.08.006_bib5","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0140-6736(60)92836-1","article-title":"Guanethidine in the treatment of hypertension","volume":"3","author":"Dollery","year":"1960","journal-title":"Lancet"},{"key":"10.1016\/j.ncl.2015.08.006_bib6","first-page":"553","article-title":"Case report: severe neurologic reaction to ciprofloxacin","volume":"47","author":"MacLeod","year":"2001","journal-title":"Can Fam Physician"},{"issue":"Suppl","key":"10.1016\/j.ncl.2015.08.006_bib7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF00543714","article-title":"Central nervous system side-effects with hydrophilic and lipophilic beta-blockers","volume":"28","author":"Westerlund","year":"1985","journal-title":"Eur J Clin Pharmacol"},{"issue":"Suppl","key":"10.1016\/j.ncl.2015.08.006_bib8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF00543713","article-title":"CNS-related side-effects with metoprolol and atenolol","volume":"28","author":"Cove-Smith","year":"1985","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ncl.2015.08.006_bib9","series-title":"Psychiatric complications of medical drugs","first-page":"73","article-title":"Mental effects of reserpine in man: a review","author":"Goodwin","year":"1972"},{"key":"10.1016\/j.ncl.2015.08.006_bib10","doi-asserted-by":"crossref","first-page":"786","DOI":"10.5694\/j.1326-5377.1973.tb110692.x","article-title":"Clonidine in the treatment of severe hypertension","volume":"1","author":"Raftos","year":"1973","journal-title":"Med J Aust"},{"issue":"2 Suppl","key":"10.1016\/j.ncl.2015.08.006_bib11","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.36076\/ppj.2008\/11\/S105","article-title":"Opioid complications and side effects","volume":"11","author":"Benyamin","year":"2008","journal-title":"Pain Physician"},{"key":"10.1016\/j.ncl.2015.08.006_bib12","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1093\/bja\/81.1.58","article-title":"Opioid tolerance: the clinical perspective","volume":"81","author":"Collett","year":"1998","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.ncl.2015.08.006_bib13","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s00213-005-2151-4","article-title":"Associative and behavioral tolerance to the analgesic effects of nicotine in rats: tail flick and paw-lick assays","volume":"180","author":"Cepeda-Benito","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ncl.2015.08.006_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/archinte.1929.00140010004001","article-title":"Opiate addiction. VI: the effects of abrupt withdrawal followed by readministration of morphine in human addicts, with special reference to the composition of the blood, the circulation and the metabolism","volume":"44","author":"Light","year":"1929","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ncl.2015.08.006_bib15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.pain.2006.07.005","article-title":"Opioids for chronic pain: taking stock","volume":"125","author":"Ballantyne","year":"2006","journal-title":"Pain"},{"key":"10.1016\/j.ncl.2015.08.006_bib16","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0885-3924(03)00047-2","article-title":"Burst ketamine to reverse opioid tolerance in cancer pain","volume":"25","author":"Mercadante","year":"2003","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.ncl.2015.08.006_bib17","doi-asserted-by":"crossref","first-page":"7650","DOI":"10.1523\/JNEUROSCI.22-17-07650.2002","article-title":"Neuronal apoptosis associated with morphine tolerance: evidence for an opioid-induced neurotoxic mechanism","volume":"22","author":"Mao","year":"2002","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.ncl.2015.08.006_bib18","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0885-3924(03)00258-6","article-title":"Hyperalgesia: an emerging iatrogenic syndrome","volume":"26","author":"Mercadante","year":"2003","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.ncl.2015.08.006_bib19","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.drugalcdep.2005.09.007","article-title":"Opioids and abnormal pain perception: new evidence from a study of chronic opioid addicts and healthy subjects","volume":"82","author":"Pud","year":"2006","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.ncl.2015.08.006_bib20","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S0959-8049(97)00205-0","article-title":"New approaches to pain control in patients with cancer","volume":"33","author":"Ahmedzai","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ncl.2015.08.006_bib21","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1345\/aph.1E309","article-title":"Pharmacologic treatment of opioid-induced sedation in chronic pain","volume":"39","author":"Reissig","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ncl.2015.08.006_bib22","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00003495-200363070-00003","article-title":"Opioid-induced bowel dysfunction: pathophysiology and potential new therapies","volume":"63","author":"Kurz","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.ncl.2015.08.006_bib23","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/clpt.1981.240","article-title":"Morphinelike arousal by methadone during sleep","volume":"30","author":"Pickworth","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ncl.2015.08.006_bib24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/J354v21n01_05","article-title":"Adverse effects of opioids on the central nervous systems of palliative care patients","volume":"21","author":"Vella-Brincat","year":"2007","journal-title":"J\u00a0Pain Palliat Care Pharmacother"},{"key":"10.1016\/j.ncl.2015.08.006_bib25","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jpainsymman.2003.07.002","article-title":"Treatment of opioid-induced delirium with acetylcholinesterase inhibitors: a case report","volume":"27","author":"Slatkin","year":"2004","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.ncl.2015.08.006_bib26","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/S0140-6736(95)92274-1","article-title":"Morphine sans Morpheus","volume":"346","author":"Hanks","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.ncl.2015.08.006_bib27","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0885-3924(03)00176-3","article-title":"Are opioid-dependent\/tolerant patients impaired in driving related skills? A structured evidence based review","volume":"25","author":"Fishbain","year":"2003","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.ncl.2015.08.006_bib28","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/jac\/27.4.405","article-title":"Neurotoxicity of beta-lactam antibiotics: predisposing factors and pathogenesis","volume":"27","author":"Schliamser","year":"1991","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.ncl.2015.08.006_bib29","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1212\/WNL.21.7.759","article-title":"Penicillinase and the convulsant action of penicillin","volume":"21","author":"Gutnick","year":"1971","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.ncl.2015.08.006_bib30","first-page":"74","article-title":"The inexplicably suicidal patient","volume":"7","author":"Murphy","year":"2008","journal-title":"Current Psychiatry"},{"issue":"3","key":"10.1016\/j.ncl.2015.08.006_bib31","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/(SICI)1520-6394(1996)4:3<139::AID-DA7>3.0.CO;2-B","article-title":"Hoigne\u2019s syndrome, kindling, and panic disorder","volume":"4","author":"Araszkiewicz","year":"1996","journal-title":"Depress Anxiety"},{"issue":"4","key":"10.1016\/j.ncl.2015.08.006_bib32","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3109\/10673229709000304","article-title":"Antibiotics: neuropsychiatric effects and psychotropic interactions","volume":"5","author":"Sternbach","year":"1997","journal-title":"Harv Rev Psychiatry"},{"key":"10.1016\/j.ncl.2015.08.006_bib33","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/MAJ.0b013e31803195e7","article-title":"Piperacillin\/tazobactam-induced seizure rapidly reversed by high flux hemodialysis in a patient on peritoneal dialysis","volume":"333","author":"Lin","year":"2007","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.ncl.2015.08.006_bib34","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s15010-009-8373-3","article-title":"Neurotoxicity associated with standard doses of piperacillin in an elderly patient with renal failure","volume":"37","author":"Huang","year":"2009","journal-title":"Infection"},{"key":"10.1016\/j.ncl.2015.08.006_bib35","first-page":"3","article-title":"Gentamicin neurotoxicity (polyneuropathy \u2013 encephalopathy)","volume":"107","author":"Bischoff","year":"1977","journal-title":"Schweiz Med Wochenschr"},{"issue":"3","key":"10.1016\/j.ncl.2015.08.006_bib36","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1365-2125.2011.03991.x","article-title":"Neurotoxic effects associated with antibiotic use: management considerations","volume":"72","author":"Grill","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ncl.2015.08.006_bib37","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1345\/aph.1L307","article-title":"Cephalosporin-induced neurotoxicity: clinical manifestations, potential pathogenic mechanisms, and the role of electroencephalographic monitoring","volume":"42","author":"Grill","year":"2008","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ncl.2015.08.006_bib38","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/ndt\/gfm713","article-title":"The neurotoxicity and safety of treatment with cefepime in patients with renal failure","volume":"23","author":"Sonck","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ncl.2015.08.006_bib39","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s10096-005-0021-y","article-title":"Neurotoxicity induced by beta-lactam antibiotics: from bench to bedside","volume":"24","author":"Chow","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ncl.2015.08.006_bib40","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0028-3908(03)00188-6","article-title":"Evidence for the involvement of GABA(A) receptor blockage in convulsions induced by cephalosporins","volume":"45","author":"Sugimoto","year":"2003","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ncl.2015.08.006_bib41","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/clpt.1990.149","article-title":"Pharmacokinetics of cefepime in subjects with renal insufficiency","volume":"48","author":"Barbhaiya","year":"1990","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ncl.2015.08.006_bib42","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1046\/j.1528-1157.2001.34701.x","article-title":"Seizures in the critically ill: the role of imipenem","volume":"42","author":"Koppel","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.ncl.2015.08.006_bib43","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00006454-199102000-00009","article-title":"Imipenem\/cilastatin treatment of bacterial meningitis in children","volume":"10","author":"Wong","year":"1991","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ncl.2015.08.006_bib44","doi-asserted-by":"crossref","first-page":"e739","DOI":"10.1542\/peds.2004-1352","article-title":"Transient psychosis in an immune-competent patient after oral trimethoprim-sulfamethoxazole administration","volume":"115","author":"Saidinejad","year":"2005","journal-title":"Pediatrics"},{"key":"10.1016\/j.ncl.2015.08.006_bib45","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/0016-5085(94)90716-1","article-title":"Central nervous system Whipple\u2019s disease: relapse during therapy with trimethoprim-sulfamethoxazole and remission with cefixime","volume":"106","author":"Cooper","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ncl.2015.08.006_bib46","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1080\/00365549850161610","article-title":"A\u00a0rare case of cotrimoxazole-induced eosinophilic aseptic meningitis in an HIV-infected patient","volume":"30","author":"Patey","year":"1998","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.ncl.2015.08.006_bib47","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1212\/WNL.43.8.1619-a","article-title":"Ciprofloxacin induced complex partial status epilepticus manifesting as an acute confusional state","volume":"43","author":"Isaacson","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2015.08.006_bib48","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/BF00860763","article-title":"Reversible encephalopathy after intravenous ciprofloxacin therapy","volume":"9","author":"Rfidah","year":"1995","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ncl.2015.08.006_bib49","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.genhosppsych.2007.11.003","article-title":"Levofloxacin-induced delirium with psychotic features","volume":"30","author":"Kiangkitiwan","year":"2008","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.ncl.2015.08.006_bib50","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/mds.20053","article-title":"Reversible orofacial dyskinesia after ofloxacin treatment","volume":"19","author":"De Bleecker","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2015.08.006_bib51","first-page":"616","article-title":"Reversible oro-facial dyskinesia in a patient receiving ciprofloxacin hydrochloride","volume":"243","author":"Pastor","year":"1996","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.ncl.2015.08.006_bib52","doi-asserted-by":"crossref","first-page":"142","DOI":"10.12968\/hosp.2000.61.2.2404","article-title":"Ciprofloxacin-induced oral-facial dyskinesia in a patient with normal liver and renal function","volume":"61","author":"Lee","year":"2000","journal-title":"Hosp Med"},{"key":"10.1016\/j.ncl.2015.08.006_bib53","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1177\/106002809603000205","article-title":"Association of a Tourette-like syndrome with ofloxacin","volume":"30","author":"Thomas","year":"1996","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ncl.2015.08.006_bib54","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1159\/000239301","article-title":"Levofloxacin, an optical isomer of ofloxacin, has attenuated epileptogenic activity in mice and inhibitory potency in GABA receptor binding","volume":"40","author":"Akahane","year":"1994","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ncl.2015.08.006_bib55","first-page":"605","article-title":"Neurotoxicity and toxicokinetics of norfloxacin in conscious rats","volume":"24","author":"Zhang","year":"2003","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.ncl.2015.08.006_bib56","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0920-1211(98)00129-6","article-title":"Depression and schizophrenia in epilepsy: social and biological risk factors","volume":"35","author":"Schmitz","year":"1999","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.ncl.2015.08.006_bib57","series-title":"Lectures on Epilepsy","first-page":"91","article-title":"Serial EEG investigations during psychotic episodes in epileptic patients and during schizophrenic attacks","author":"Landolt","year":"1958"},{"key":"10.1016\/j.ncl.2015.08.006_bib58","first-page":"190","article-title":"Epilepsie als ansfallsleiden und als psychose. Uber alternative Psychosen paranoider Pragung bei forcierter Normal-isierung (Landolt) des Elektroenzephalogramms spileptischer","volume":"36","author":"Tellenbach","year":"1965","journal-title":"Nervenarzt"},{"issue":"Suppl 10","key":"10.1016\/j.ncl.2015.08.006_bib59","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1111\/j.1528-1157.1999.tb00887.x","article-title":"Psychiatric syndromes related to antiepileptic drugs","volume":"40","author":"Schmitz","year":"1999","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.ncl.2015.08.006_bib60","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1684\/epd.2008.0229","article-title":"Catatonic psychosis related to forced normalization in a girl with Dravet\u2019s syndrome","volume":"10","author":"Gobbi","year":"2008","journal-title":"Epileptic Disord"},{"issue":"5","key":"10.1016\/j.ncl.2015.08.006_bib61","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s10072-011-0869-9","article-title":"Vulnerability of an epileptic case to psychosis: sodium valproate with lamotrigine, forced normalization, postictal psychosis or all?","volume":"33","author":"Turan","year":"2012","journal-title":"Neurol Sci"},{"key":"10.1016\/j.ncl.2015.08.006_bib62","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1528-1157.1987.tb03659.x","article-title":"Phenomenology of depression in epilepsy","volume":"28","author":"Robertson","year":"1987","journal-title":"Epilepsia"},{"key":"10.1016\/j.ncl.2015.08.006_bib63","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0002-7138(09)60232-6","article-title":"Overrepresentation of epileptics in a consecutive series of suicide attempters seen at a children\u2019s hospital, 1978\u20131983","volume":"25","author":"Brent","year":"1986","journal-title":"J\u00a0Am Acad Child Psychiatry"},{"key":"10.1016\/j.ncl.2015.08.006_bib64","first-page":"909","article-title":"Phenobarbital treatment and major depressive disorder in children with epilepsy","volume":"80","author":"Brent","year":"1987","journal-title":"Pediatrics"},{"key":"10.1016\/j.ncl.2015.08.006_bib65","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1001\/jama.1975.03240220043019","article-title":"Delayed idiosyncratic psychosis with diphenylhydantoin","volume":"231","author":"McDanal","year":"1975","journal-title":"JAMA"},{"key":"10.1016\/j.ncl.2015.08.006_bib66","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1046\/j.1528-1157.2001.09000.x","article-title":"Reexamination of interictal psychoses based on DSM IV psychosis classification and international epilepsy classification","volume":"42","author":"Kanemoto","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.ncl.2015.08.006_bib67","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1017\/S0033291700013726","article-title":"Anticonvulsant drugs and mental symptoms: a review","volume":"6","author":"Trimble","year":"1976","journal-title":"Psychol Med"},{"key":"10.1016\/j.ncl.2015.08.006_bib68","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1046\/j.1528-1157.2002.25001.x","article-title":"Serum and CSF glutamine levels in valproate-related hyperammonemic encephalopathy","volume":"43","author":"Vossler","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.ncl.2015.08.006_bib69","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1212\/WNL.54.1.230","article-title":"Valproic acid induced hyperammonemic encephalopathy in the presence of topiramate","volume":"54","author":"Hamer","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2015.08.006_bib70","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1212\/WNL.51.1.292","article-title":"Fulminant progression of demyelinating disease after valproate-induced encephalopathy","volume":"51","author":"Blindauer","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2015.08.006_bib71","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1023\/A:1021918104127","article-title":"Valproate-induced hyperammonemic encephalopathy","volume":"17","author":"Verrotti","year":"2002","journal-title":"Metab Brain Dis"},{"key":"10.1016\/j.ncl.2015.08.006_bib72","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1016\/0006-2952(89)90675-8","article-title":"Valproate-induced hyperammonemia of renal origin","volume":"38","author":"Rumbach","year":"1989","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ncl.2015.08.006_bib73","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1651-2227.1996.tb14058.x","article-title":"The effect of carnitine supplementation in valproate-induced hyperammonemia","volume":"85","author":"Bohles","year":"1996","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.ncl.2015.08.006_bib74","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1345\/aph.19242","article-title":"The role of carnitine supplementation during valproic acid therapy","volume":"34","author":"Raskind","year":"2000","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ncl.2015.08.006_bib75","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1528-1157.1984.tb05639.x","article-title":"Psychiatric complications of absence therapy and their relation to alteration of sleep","volume":"25","author":"Wolf","year":"1984","journal-title":"Epilepsia"},{"key":"10.1016\/j.ncl.2015.08.006_bib76","first-page":"331","article-title":"Behavioral effects of carbamazepine","volume":"vol. 11","author":"Dalby","year":"1975"},{"key":"10.1016\/j.ncl.2015.08.006_bib77","first-page":"1105","article-title":"Manic state with carbamazepine therapy of seizures","volume":"78","author":"Drake","year":"1986","journal-title":"J\u00a0Natl Med Assoc"},{"key":"10.1016\/j.ncl.2015.08.006_bib78","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1136\/jnnp.54.5.435","article-title":"Vigabatrin and psychosis","volume":"54","author":"Sander","year":"1991","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ncl.2015.08.006_bib79","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0920-1211(96)00016-2","article-title":"Vigabatrin and behaviour disorders: a retrospective study","volume":"25","author":"Thomas","year":"1996","journal-title":"Epilepsy Res"},{"issue":"Suppl 2","key":"10.1016\/j.ncl.2015.08.006_bib80","first-page":"30","article-title":"Vigabatrin in childhood epilepsy","volume":"6","author":"Dulac","year":"1991","journal-title":"J\u00a0Child Neurol"},{"key":"10.1016\/j.ncl.2015.08.006_bib81","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2165\/00003495-199550040-00008","article-title":"Lamotrigine","volume":"50","author":"Fitton","year":"1995","journal-title":"Drugs"},{"key":"10.1016\/j.ncl.2015.08.006_bib82","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(95)90581-2","article-title":"Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine\/Carbamazepine Monotherapy trial group","volume":"345","author":"Brodie","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.ncl.2015.08.006_bib83","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2165\/00002018-200124070-00004","article-title":"Behavioural effects of the new anticonvulsants","volume":"24","author":"Besag","year":"2001","journal-title":"Drug Saf"},{"key":"10.1016\/j.ncl.2015.08.006_bib84","series-title":"Epilepsy. A comprehensive textbook","first-page":"1531","article-title":"Lamotrigine","author":"Binnie","year":"1997"},{"key":"10.1016\/j.ncl.2015.08.006_bib85","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1212\/WNL.52.6.1191","article-title":"Lamotrigine-induced tourettism","volume":"52","author":"Lombroso","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2015.08.006_bib86","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1528-1157.1996.tb00517.x","article-title":"Behavioral side effects of gabapentin in children","volume":"37","author":"Lee","year":"1996","journal-title":"Epilepsia"},{"key":"10.1016\/j.ncl.2015.08.006_bib87","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/j.1528-1157.1995.tb01063.x","article-title":"Gabapentin toxicity in children manifesting as behavioral changes","volume":"36","author":"Wolf","year":"1996","journal-title":"Epilepsia"},{"key":"10.1016\/j.ncl.2015.08.006_bib88","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1059-1311(96)80111-7","article-title":"Tiagabine and non-convulsive status epilepticus","volume":"5","author":"Schapel","year":"1996","journal-title":"Seizure"},{"issue":"Suppl 6","key":"10.1016\/j.ncl.2015.08.006_bib89","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1528-1157.1995.tb06009.x","article-title":"Tiagabine: the safety landscape","volume":"36","author":"Leppik","year":"1995","journal-title":"Epilepsia"},{"key":"10.1016\/j.ncl.2015.08.006_bib90","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.yebeh.2003.07.009","article-title":"The influence of comorbid depression on quality of life for people with epilepsy","volume":"4","author":"Cramer","year":"2003","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ncl.2015.08.006_bib91","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1046\/j.1528-1157.2003.05402.x","article-title":"Topiramate and psychiatric adverse events in patients with epilepsy","volume":"44","author":"Mula","year":"2003","journal-title":"Epilepsia"},{"key":"10.1016\/j.ncl.2015.08.006_bib92","unstructured":"Janssen-Cilag. Topamax. Product monograph, 1996."},{"key":"10.1016\/j.ncl.2015.08.006_bib93","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1212\/01.WNL.0000078031.32904.0D","article-title":"Psychiatric adverse events during levetiracetam therapy","volume":"61","author":"Mula","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2015.08.006_bib94","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1136\/jnnp.67.2.231","article-title":"Epileptic psychoses and anticonvulsant drug treatment","volume":"67","author":"Matsuura","year":"1999","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ncl.2015.08.006_bib95","series-title":"Epilepsy. A comprehensive textbook","first-page":"2161","article-title":"Neuropsychiatric consequences of pharmacotherapy","author":"Trimble","year":"1997"},{"issue":"Suppl 2","key":"10.1016\/j.ncl.2015.08.006_bib96","first-page":"53","article-title":"Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders","volume":"53","author":"Ketter","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2015.08.006_bib97","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1136\/adc.2003.041541","article-title":"Adverse psychological effects of corticosteroids in children and adolescents","volume":"90","author":"Stuart","year":"2005","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.ncl.2015.08.006_bib98","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/00006842-195203000-00004","article-title":"Psychiatric observations in patients treated with cortisone and ACTH","volume":"14","author":"Brody","year":"1952","journal-title":"Psychosom Med"},{"key":"10.1016\/j.ncl.2015.08.006_bib99","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/qjmed\/89.7.543","article-title":"Psychiatric aspects of Cushing\u2019s syndrome","volume":"89","author":"Kelly","year":"1996","journal-title":"QJM"},{"key":"10.1016\/j.ncl.2015.08.006_bib100","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1055\/s-2007-1014405","article-title":"Psychiatric phenomenology in Cushing\u2019s disease","volume":"25","author":"Loosen","year":"1992","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.ncl.2015.08.006_bib101","first-page":"3196","article-title":"Long-term outcome for children and adolescents following transphenoidal surgery for Cushing disease","volume":"82","author":"Devoe","year":"1997","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ncl.2015.08.006_bib102","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1177\/000992289002900704","article-title":"Mental status changes in children receiving glucocorticoids: review of the literature","volume":"29","author":"Satel","year":"1990","journal-title":"Clin Pediatr"},{"key":"10.1016\/j.ncl.2015.08.006_bib103","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/archpsyc.1981.01780290105011","article-title":"Side effects of corticosteroid therapy: psychiatric aspects","volume":"38","author":"Ling","year":"1981","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.ncl.2015.08.006_bib104","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0165-0327(83)90022-8","article-title":"Steroid-induced psychiatric syndromes","volume":"5","author":"Lewis","year":"1983","journal-title":"J\u00a0Affect Disord"},{"key":"10.1016\/j.ncl.2015.08.006_bib105","series-title":"Principles of corticosteroid therapy","first-page":"174","article-title":"Corticosteroids and behavioural disturbances","author":"Halper","year":"2002"},{"key":"10.1016\/j.ncl.2015.08.006_bib106","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3109\/07357908909041378","article-title":"Corticosteroids in cancer: neuropsychiatric complications","volume":"7","author":"Steifel","year":"1989","journal-title":"Cancer Invest"},{"key":"10.1016\/j.ncl.2015.08.006_bib107","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/cpt1972135part1694","article-title":"Acute adverse reactions to prednisone in relation to dosage","volume":"13","author":"The Boston Collaborative Drug Surveillance Program","year":"1972","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ncl.2015.08.006_bib108","first-page":"57","article-title":"Exogenous corticosteroid effects on mood and cognition: case presentations","volume":"37","author":"Reckart","year":"1990","journal-title":"Int J Psychosom"},{"key":"10.1016\/j.ncl.2015.08.006_bib109","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3109\/10401238909149964","article-title":"Steroid withdrawal psychiatric syndromes","volume":"1","author":"Fricchione","year":"1989","journal-title":"Ann Clin Psychiatry"},{"key":"10.1016\/j.ncl.2015.08.006_bib110","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1749-6632.1997.tb48381.x","article-title":"Glucorticoid medication, memory and steroid psychosis in medical illness","volume":"823","author":"Wolkowitz","year":"1997","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ncl.2015.08.006_bib111","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0163-7258(02)00297-8","article-title":"Mechanisms involved in the side effects of glucocorticoids","volume":"96","author":"Schacke","year":"2002","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.ncl.2015.08.006_bib112","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0306-4530(94)90064-7","article-title":"Prospective controlled studies of the behavioural and biological effects of exogenous corticosteroids","volume":"19","author":"Wolkowitz","year":"1994","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.ncl.2015.08.006_bib113","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0006-8993(85)90638-9","article-title":"Down regulation of neural corticosterone receptors by corticosterone and dexamethasone","volume":"339","author":"Sapolsky","year":"1985","journal-title":"Brain Res"},{"key":"10.1016\/j.ncl.2015.08.006_bib114","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1749-6632.1997.tb48392.x","article-title":"The brain is an important target of adrenal steroid actions. A comparison of synthetic and natural steroids","volume":"823","author":"McEwen","year":"1997","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ncl.2015.08.006_bib115","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0893-133X(99)00054-8","article-title":"Hippocampal remodelling and damage by corticosteroids. Implications for mood disorders","volume":"21","author":"Brown","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ncl.2015.08.006_bib116","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1210\/edrv-7-3-284","article-title":"The neuroendocrinology of stress and aging: the glucocorticoid cascade hypothesis","volume":"7","author":"Sapolsky","year":"1986","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ncl.2015.08.006_bib117","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1523\/JNEUROSCI.21-01-00330.2001","article-title":"Heterogeneity of hippocampal GABAA receptors: regulation by corticosterone","volume":"21","author":"Orchinik","year":"2001","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.ncl.2015.08.006_bib118","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(03)12517-2","article-title":"An organic cause of neuropsychiatric illness in adolescence","volume":"361","author":"Taylor","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ncl.2015.08.006_bib119","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/00004714-198204000-00002","article-title":"Cortisol\u2019s effect on human mental functioning","volume":"2","author":"Carpenter","year":"1982","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.ncl.2015.08.006_bib120","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S0889-8529(02)00008-7","article-title":"Glucocorticoid withdrawal schemes in chronic medical disorders: a systemic review","volume":"31","author":"Richter","year":"2002","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.ncl.2015.08.006_bib121","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/0002-9343(80)90358-7","article-title":"On the various forms of corticosteroid withdrawal syndrome","volume":"68","author":"Dixon","year":"1980","journal-title":"Am J Med"},{"key":"10.1016\/j.ncl.2015.08.006_bib122","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1177\/070674378803300711","article-title":"Secondary mania with steroid withdrawal","volume":"33","author":"Venkatarangam","year":"1988","journal-title":"Can J Psychiatry"},{"issue":"Suppl 2","key":"10.1016\/j.ncl.2015.08.006_bib123","first-page":"S323","article-title":"Drug-induced impulse control disorders in Parkinson\u2019s disease","volume":"258","author":"Reiff","year":"2011","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.ncl.2015.08.006_bib124","series-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association (APA)","year":"2000"},{"key":"10.1016\/j.ncl.2015.08.006_bib125","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.parkreldis.2007.04.006","article-title":"The thrill of reckless driving in patients with Parkinson\u2019s disease: an additional behavioural phenomenon in dopamine dysregulation syndrome?","volume":"14","author":"Avanzi","year":"2008","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.ncl.2015.08.006_bib126","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1002\/mds.22505","article-title":"Impulsive and compulsive behaviors in Parkinson\u2019s disease","volume":"24","author":"Evans","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2015.08.006_bib127","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/jnnp.68.4.423","article-title":"Hedonistic homeostatic dysregulation in patients with Parkinson\u2019s disease on dopamine replacement therapies","volume":"68","author":"Giovannoni","year":"2000","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ncl.2015.08.006_bib128","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2165\/00002018-200932060-00004","article-title":"Behavioural adverse effects of dopaminergic treatments in Parkinson\u2019s disease: incidence, neurobiological basis, management and prevention","volume":"32","author":"Antonini","year":"2009","journal-title":"Drug Saf"},{"key":"10.1016\/j.ncl.2015.08.006_bib129","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0893-133X(02)00366-4","article-title":"Amphetamine-induced increases in\u00a0extracellular dopamine, drug wanting, and novelty seeking: a PET\/[11C]raclopride\u00a0study in healthy men","volume":"27","author":"Leyton","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ncl.2015.08.006_bib130","doi-asserted-by":"crossref","first-page":"13213","DOI":"10.1523\/JNEUROSCI.3446-06.2006","article-title":"Preference for immediate over delayed rewards is associated with magnitude of ventral striatal activity","volume":"26","author":"Hariri","year":"2006","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.ncl.2015.08.006_bib131","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1176\/appi.ajp.162.8.1403","article-title":"The neural basis of addiction: a pathology of motivation and choice","volume":"162","author":"Kalivas","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.ncl.2015.08.006_bib132","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1093\/brain\/awp054","article-title":"Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C]raclopride PET study","volume":"132","author":"Steeves","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.ncl.2015.08.006_bib133","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/mds.22571","article-title":"Validation of the questionnaire for impulsive-compulsive disorders in Parkinson\u2019s disease","volume":"24","author":"Weintraub","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2015.08.006_bib134","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/mds.21770","article-title":"Long-term follow-up of impulse control disorders in Parkinson\u2019s disease","volume":"23","author":"Mamikonyan","year":"2008","journal-title":"Mov Disord"},{"issue":"5","key":"10.1016\/j.ncl.2015.08.006_bib135","first-page":"48","article-title":"Parkinson\u2019s disease-related disorders in the impulsive-compulsive spectrum","volume":"255","author":"Wolters","year":"2008","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.ncl.2015.08.006_bib136","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/ana.22029","article-title":"Pathological gambling in Parkinson disease is reduced by amantadine","volume":"68","author":"Thomas","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ncl.2015.08.006_bib137","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jocn.2008.12.010","article-title":"Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson\u2019s disease","volume":"16","author":"Lim","year":"2009","journal-title":"J\u00a0Clin Neurosci"},{"key":"10.1016\/j.ncl.2015.08.006_bib138","first-page":"335","article-title":"Pharmacogenetics and antipsychotics in the light of personalized pharmacotherapy","volume":"22","author":"Mihaljevic-Peles","year":"2010","journal-title":"Psychiatr Danub"},{"key":"10.1016\/j.ncl.2015.08.006_bib139","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1080\/07853890600551045","article-title":"Pharmacogenomics and antidepressant drugs","volume":"38","author":"Binder","year":"2006","journal-title":"Ann Med"},{"key":"10.1016\/j.ncl.2015.08.006_bib140","first-page":"53","article-title":"Safety and efficacy pharmacogenomics in pediatric psychopharmacology","volume":"17","author":"Wall","year":"2010","journal-title":"Prim Psychiatry"},{"key":"10.1016\/j.ncl.2015.08.006_bib141","doi-asserted-by":"crossref","first-page":"341","DOI":"10.4088\/JCP.v65n0309","article-title":"The cost consequences of treatment-resistant depression","volume":"65","author":"Russell","year":"2004","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.ncl.2015.08.006_bib142","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1097\/00019442-200512000-00002","article-title":"Looking forward in geriatric anxiety and depression: implications of basic science for the future","volume":"13","author":"Gershenfeld","year":"2005","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.ncl.2015.08.006_bib143","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/00004714-198704000-00004","article-title":"Long-term versus short-term amitriptyline side effects as measured by a postmarketing surveillance system","volume":"7","author":"Bryant","year":"1987","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.ncl.2015.08.006_bib144","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1176\/ajp.134.4.461","article-title":"Overdosing the tricyclic overdose patient","volume":"134","author":"Biggs","year":"1977","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.ncl.2015.08.006_bib145","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1001\/jama.1977.03280020039020","article-title":"Tricyclic antidepressant overdose: incidence of symptoms","volume":"238","author":"Biggs","year":"1977","journal-title":"JAMA"},{"key":"10.1016\/j.ncl.2015.08.006_bib146","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/clpt.1986.173","article-title":"Disposition of single oral doses of e-10-hydroxynortriptyline\u00a0in healthy subjects, with some observations on pharmacodynamic effects","volume":"40","author":"Bertilsson","year":"1986","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ncl.2015.08.006_bib147","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0009-9236(98)90040-6","article-title":"10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes","volume":"63","author":"Dalen","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ncl.2015.08.006_bib148","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00004714-200004000-00005","article-title":"Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: impact of CYP2D6 genotype on the hydroxylation of nortriptyline","volume":"20","author":"Morita","year":"2000","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.ncl.2015.08.006_bib149","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1176\/appi.psy.47.1.75","article-title":"Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19","volume":"47","author":"De Leon","year":"2006","journal-title":"Psychosomatics"},{"key":"10.1016\/j.ncl.2015.08.006_bib150","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.4065\/82.9.1065","article-title":"Cytochrome P450 2D6 genotype variation and venlafaxine dosage","volume":"82","author":"McAlpine","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ncl.2015.08.006_bib151","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s12024-010-9188-3","article-title":"Review: pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects","volume":"7","author":"Pilgrim","year":"2011","journal-title":"Forensic Sci Med Pathol"},{"key":"10.1016\/j.ncl.2015.08.006_bib152","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1345\/aph.1C021","article-title":"Serotonin syndrome induced by low-dose venlafaxine","volume":"37","author":"Pan","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ncl.2015.08.006_bib153","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s13181-010-0013-x","article-title":"A\u00a0comparison of venlafaxine and SSRIS in deliberate self-poisoning","volume":"6","author":"Chan","year":"2010","journal-title":"J\u00a0Med Toxicol"},{"key":"10.1016\/j.ncl.2015.08.006_bib154","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1176\/ajp.151.7.979","article-title":"The prevalence and distribution of major depression in a national community sample: the national comorbidity study","volume":"151","author":"Blazer","year":"1994","journal-title":"Am J Psychiatry"},{"issue":"2","key":"10.1016\/j.ncl.2015.08.006_bib155","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0193-953X(05)70286-0","article-title":"Management of psychotic, treatment-resistant depression","volume":"19","author":"Rothschild","year":"1996","journal-title":"Psychiatr Clin North Am"},{"issue":"11\u201312","key":"10.1016\/j.ncl.2015.08.006_bib156","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2298\/MPNS1212521P","article-title":"Extrapyramidal syndromes caused by antipsychotics","volume":"65","author":"Poznic Jesic","year":"2012","journal-title":"Med Pregl"},{"issue":"1","key":"10.1016\/j.ncl.2015.08.006_bib157","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2165\/00002018-199819010-00005","article-title":"Managing antipsychotic-induced acute and tardive dystonia","volume":"19","author":"Raja","year":"1998","journal-title":"Drug Saf"},{"issue":"3","key":"10.1016\/j.ncl.2015.08.006_bib158","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/10673220600748486","article-title":"Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome","volume":"14","author":"Shirzadi","year":"2006","journal-title":"Harv Rev Psychiatry"},{"key":"10.1016\/j.ncl.2015.08.006_bib159","series-title":"DSM-IV source book","first-page":"623","article-title":"\u201cAcute dystonia induced by drug treatment\u201d","author":"van Harten","year":"1994"},{"issue":"3","key":"10.1016\/j.ncl.2015.08.006_bib160","first-page":"105","article-title":"Motor and mental aspects of extrapyramidal syndromes","volume":"10","author":"Casey","year":"1995","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.ncl.2015.08.006_bib161","series-title":"Practice guideline for the treatment of schizophrenia","author":"Lehan","year":"2004"},{"key":"10.1016\/j.ncl.2015.08.006_bib162","first-page":"1223","article-title":"Long term treatment with risperidone long-acting injectable in patients with schizophrenia","volume":"12","author":"Kamishima","year":"2009","journal-title":"Jpn J Psychiatry Neurol"},{"issue":"3","key":"10.1016\/j.ncl.2015.08.006_bib163","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1176\/appi.ajp.162.3.625-a","article-title":"Ziprasidone-induced acute dystonia","volume":"162","author":"Mason","year":"2005","journal-title":"Am J Psychiatry"},{"issue":"3","key":"10.1016\/j.ncl.2015.08.006_bib164","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1080\/10550490701375343","article-title":"A\u00a0case of acute dystonia after single dose of aripiprazole in a man with cocaine dependence","volume":"16","author":"Henderson","year":"2007","journal-title":"Am J Addict"},{"issue":"1004","key":"10.1016\/j.ncl.2015.08.006_bib165","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/pgmj.2008.073312","article-title":"Drug induced parkinsonism: a common cause of parkinsonism in older people","volume":"85","author":"Thanvi","year":"2009","journal-title":"Postgrad Med J"},{"issue":"8","key":"10.1016\/j.ncl.2015.08.006_bib166","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1176\/appi.ajp.160.8.1396","article-title":"Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol","volume":"160","author":"Lieberman","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.ncl.2015.08.006_bib167","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.2147\/DDDT.S32328","article-title":"New and emerging treatments for symptomatic tardive dyskinesia","volume":"7","author":"Rana","year":"2013","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.ncl.2015.08.006_bib168","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1192\/bjp.171.3.265","article-title":"Prevalence of spontaneous dyskinesia in schizophrenic and non-schizophrenic psychiatric patients","volume":"171","author":"Fenton","year":"1997","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.ncl.2015.08.006_bib169","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/S0920-9964(98)00160-1","article-title":"Tardive dyskinesia and atypical antipsychotic drugs","volume":"35","author":"Casey","year":"1999","journal-title":"Schizophr Res"},{"issue":"3","key":"10.1016\/j.ncl.2015.08.006_bib170","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0924-9338(02)00647-8","article-title":"Tardive dyskinesias and antipsychotics: a review","volume":"17","author":"Llorca","year":"2002","journal-title":"Eur Psychiatry"},{"issue":"11","key":"10.1016\/j.ncl.2015.08.006_bib171","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1177\/070674370505001110","article-title":"Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: incidence and management strategies in patients with schizophrenia","volume":"50","author":"Margolese","year":"2005","journal-title":"Can J Psychiatry"},{"issue":"4","key":"10.1016\/j.ncl.2015.08.006_bib172","doi-asserted-by":"crossref","first-page":"463","DOI":"10.4088\/JCP.07m03890yel","article-title":"Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study","volume":"71","author":"Woods","year":"2010","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.ncl.2015.08.006_bib173","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/00002030-200206140-00002","article-title":"Neurologic and psychiatric complications of antiretroviral agents","volume":"16","author":"Treisman","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.ncl.2015.08.006_bib174","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/archpsyc.58.8.721","article-title":"Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States","volume":"58","author":"Bing","year":"2001","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.ncl.2015.08.006_bib175","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1089\/apc.1999.13.153","article-title":"HIV associated dementia: new insights into disease pathogenesis and therapeutic interventions","volume":"13","author":"Swindells","year":"1999","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.ncl.2015.08.006_bib176","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/09540120050042990","article-title":"The changing patterns of mental health problems in HIV infection: the view from London, UK","volume":"12","author":"Catalan","year":"2000","journal-title":"AIDS Care"},{"key":"10.1016\/j.ncl.2015.08.006_bib177","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1097\/00002030-199818000-00004","article-title":"Lest we forget: neuropsychiatry and the new generation anti-HIV Drugs","volume":"12","author":"Gonzalez","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.ncl.2015.08.006_bib178","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1258\/0956462001916146","article-title":"Indinavir use: associated reversible hair loss and mood disturbance","volume":"11","author":"Harry","year":"2000","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.ncl.2015.08.006_bib179","series-title":"Guidelines for the prescribing of medication for mental health disorders for people with HIV infection (draft) (council report CR127)","author":"Everall","year":"2004"},{"key":"10.1016\/j.ncl.2015.08.006_bib180","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1046\/j.1468-1293.2003.00142.x","article-title":"Antiretroviral therapy-induced psychosis: case report and brief review of the literature","volume":"4","author":"Foster","year":"2003","journal-title":"HIV Med"},{"key":"10.1016\/j.ncl.2015.08.006_bib181","first-page":"290","article-title":"Apropos of atypical melancholia with Sustiva (efavirenz)","volume":"27","author":"Lang","year":"2001","journal-title":"Encephale"},{"key":"10.1016\/j.ncl.2015.08.006_bib182","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1097\/00002030-200107060-00021","article-title":"Management of sudden psychiatric disorders related to efavirenz","volume":"15","author":"Peyriere","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.ncl.2015.08.006_bib183","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1592\/phco.22.11.930.33624","article-title":"Central nervous system adverse effects with efavirenz: case report and review","volume":"22","author":"Puzantian","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ncl.2015.08.006_bib184","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1097\/00002030-199905070-00024","article-title":"Reply to Gonzalez and Everall: lest we forget: neuropsychiatry and the new generation anti-HIV Drugs","volume":"13","author":"Colebunders","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.ncl.2015.08.006_bib185","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1097\/00002030-200109280-00033","article-title":"Efavirenz-induced psychosis","volume":"15","author":"Sanz de la Garza","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.ncl.2015.08.006_bib186","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1345\/aph.18240","article-title":"Significant interactions with new antiretrovirals and psychotropic drugs","volume":"33","author":"Tseng","year":"1999","journal-title":"Ann Pharmacother"},{"issue":"337","key":"10.1016\/j.ncl.2015.08.006_bib187","first-page":"3","article-title":"St John\u2019s wort warning: do not combine with protease inhibitors, NNRTIs","volume":"18","author":"James","year":"2000","journal-title":"AIDS Treat News"},{"key":"10.1016\/j.ncl.2015.08.006_bib188","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0006-3223(97)00552-0","article-title":"Differential sensitivities to risperidone and olanzapine in a human immunodeficiency virus patient","volume":"44","author":"Meyer","year":"1998","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.ncl.2015.08.006_bib189","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/1531-8257(199901)14:1<128::AID-MDS1021>3.0.CO;2-J","article-title":"Pilot study with clozapine in patients with HIV-associated psychosis and drug-induced parkinsonism","volume":"14","author":"Lera","year":"1999","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2015.08.006_bib190","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1345\/aph.1A447","article-title":"Interactions between recreational drugs and antiretroviral agents","volume":"36","author":"Antoniou","year":"2002","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ncl.2015.08.006_bib191","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3389\/fnins.2015.00131","article-title":"Mechanisms of chemotherapy-induced behavioral toxicities","volume":"9","author":"Vichaya","year":"2015","journal-title":"Front Neurosci"},{"key":"10.1016\/j.ncl.2015.08.006_bib192","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1002\/cncr.11382","article-title":"Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms","volume":"97","author":"Cleeland","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ncl.2015.08.006_bib193","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.tins.2013.10.003","article-title":"The neuroimmune basis of fatigue","volume":"37","author":"Dantzer","year":"2014","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.ncl.2015.08.006_bib194","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1200\/JCO.2007.10.7805","article-title":"Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer","volume":"26","author":"Miller","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ncl.2015.08.006_bib195","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1124\/pr.113.008144","article-title":"Neuroinflammation and comorbidity of pain and depression","volume":"66","author":"Walker","year":"2014","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.ncl.2015.08.006_bib196","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1200\/JCO.2001.19.14.3385","article-title":"Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors","volume":"19","author":"Cella","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ncl.2015.08.006_bib197","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.ejca.2005.11.026","article-title":"Cancer-related fatigue: a critical appraisal","volume":"42","author":"Prue","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ncl.2015.08.006_bib198","doi-asserted-by":"crossref","first-page":"904","DOI":"10.6004\/jnccn.2010.0067","article-title":"Cancer-related fatigue","volume":"8","author":"Berger","year":"2010","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.ncl.2015.08.006_bib199","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0037-1963(00)90063-5","article-title":"Impact of fatigue on quality of life in oncology patients","volume":"37","author":"Curt","year":"2000","journal-title":"Semin Hematol"},{"key":"10.1016\/j.ncl.2015.08.006_bib200","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1080\/02640419508732277","article-title":"Central and peripheral factors in fatigue","volume":"13","author":"Davis","year":"1995","journal-title":"J\u00a0Sports Sci"},{"key":"10.1016\/j.ncl.2015.08.006_bib201","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0022-510X(00)00411-1","article-title":"Fatigue and basal ganglia","volume":"179","author":"Chaudhuri","year":"2000","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.ncl.2015.08.006_bib202","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0885-3924(02)00388-3","article-title":"Preliminary evaluation of a clinical syndrome approach to assessing cancer-related fatigue","volume":"23","author":"Sadler","year":"2002","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.ncl.2015.08.006_bib203","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s00520-004-0734-y","article-title":"Comparison of proposed diagnostic criteria with FACT-F and VAS for cancer-related fatigue: proposal for use as a screening tool","volume":"13","author":"Van Belle","year":"2005","journal-title":"Support Care Cancer"},{"issue":"Suppl 6","key":"10.1016\/j.ncl.2015.08.006_bib204","first-page":"23","article-title":"Physical components of depression and psychomotor retardation","volume":"67","author":"Lecrubier","year":"2006","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.ncl.2015.08.006_bib205","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1093\/annonc\/mdm353","article-title":"Requestioning depression in patients with cancer: contribution of somatic and affective symptoms to Beck's Depression Inventory","volume":"18","author":"Wedding","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ncl.2015.08.006_bib206","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1099800406290932","article-title":"The cancer chemotherapy drug etoposide (VP-16) induces proinflammatory cytokine production and sickness behavior-like symptoms in a mouse model of cancer chemotherapy-related symptoms","volume":"8","author":"Wood","year":"2006","journal-title":"Biol Res Nurs"},{"key":"10.1016\/j.ncl.2015.08.006_bib207","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.neubiorev.2011.12.012","article-title":"The use of a running wheel to measure activity in rodents: relationship to energy balance, general activity, and reward","volume":"36","author":"Novak","year":"2012","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.ncl.2015.08.006_bib208","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.ctrv.2012.05.002","article-title":"Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review","volume":"38","author":"Hutchinson","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ncl.2015.08.006_bib209","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s11912-013-0307-7","article-title":"Clearing the air: a review of our current understanding of \u201cchemo fog\u201d","volume":"15","author":"O'farrell","year":"2013","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ncl.2015.08.006_bib210","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1002\/cncr.28323","article-title":"Acute cognitive impairment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant","volume":"119","author":"Jones","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.ncl.2015.08.006_bib211","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"key":"10.1016\/j.ncl.2015.08.006_bib212","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.bbi.2004.08.004","article-title":"Immune-to-brain communication dynamically modulates pain: physiological and pathological consequences","volume":"19","author":"Wieseler-Frank","year":"2005","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.ncl.2015.08.006_bib213","first-page":"168","article-title":"Recognition of damage-associated molecular patterns related to nucleic acids during inflammation and vaccination","volume":"2","author":"Jounai","year":"2012","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.ncl.2015.08.006_bib214","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.bbr.2009.10.009","article-title":"Methotrexate reduces hippocampal blood vessel density and activates microglia in rats but does not elevate central cytokine release","volume":"207","author":"Seigers","year":"2010","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.ncl.2015.08.006_bib215","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/jnci\/djt073","article-title":"Cognitive complaints after breast cancer treatments: examining the relationship with neuropsychological test performance","volume":"105","author":"Ganz","year":"2013","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.ncl.2015.08.006_bib216","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10549-006-9380-z","article-title":"Altered frontocortical cerebellar, and basal ganglia activity in adjuvant treated breast cancer survivors 5-10 years after chemotherapy","volume":"103","author":"Silverman","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ncl.2015.08.006_bib217","unstructured":"Doctors are finding it harder to deny \u201cchemobrain\u201d. The Virginian-Pilot October 2, 2007."},{"issue":"15","key":"10.1016\/j.ncl.2015.08.006_bib218","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1176\/pn.42.15.0031","article-title":"Modafinil relieves cognitive chemotherapy side effects","volume":"42","author":"Whyche","year":"2007","journal-title":"Psychiatric News"},{"issue":"4","key":"10.1016\/j.ncl.2015.08.006_bib219","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2325\/jbcs.12.279","article-title":"Mild cognitive impairment after adjuvant chemotherapy in breast cancer patients\u2013evaluation of appropriate research design and methodology to measure symptoms","volume":"12","author":"Matsuda","year":"2005","journal-title":"Breast Cancer"},{"key":"10.1016\/j.ncl.2015.08.006_bib220","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/jhep.2003.50031","article-title":"Adherence and mental side effects during hepatitis C treatment with interferon alfa a ribavirin in psychiatric risk groups","volume":"34","author":"Schaefer","year":"2003","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1016\/j.ncl.2015.08.006_bib221","first-page":"39","article-title":"Mood and cognitive side effects of interferon-a therapy","volume":"25","author":"Valentine","year":"1998","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ncl.2015.08.006_bib222","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1176\/appi.ajp.157.6.867","article-title":"Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review","volume":"157","author":"Dieperink","year":"2000","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.ncl.2015.08.006_bib223","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0168-8278(05)80402-7","article-title":"Suicide associated with alfa interferon therapy for chronic viral hepatitis","volume":"21","author":"Janssen","year":"1994","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.ncl.2015.08.006_bib224","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0165-1781(01)00315-8","article-title":"Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms","volume":"105","author":"Bonaccorso","year":"2001","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.ncl.2015.08.006_bib225","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/sj.mp.4000872","article-title":"Treatment with interferon-alpha (INF\u03b1) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to INF\u03b1-induced depressive and anxiety symptoms and immune activation","volume":"6","author":"Maes","year":"2001","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.ncl.2015.08.006_bib226","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1089\/107999001300177457","article-title":"Neuropsychiatric effects and type of INF-\u03b1 in chronic hepatitis C","volume":"21","author":"Malaguarnera","year":"2001","journal-title":"J\u00a0Interferon Cytokine Res"},{"key":"10.1016\/j.ncl.2015.08.006_bib227","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/sj.mp.4001119","article-title":"A\u00a0prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C","volume":"7","author":"Hauser","year":"2002","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.ncl.2015.08.006_bib228","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","article-title":"An inventory for measuring depression","volume":"4","author":"Beck","year":"1961","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.ncl.2015.08.006_bib229","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1053\/jhep.2000.7880","article-title":"Hepatitis C, interferon alfa, and depression","volume":"31","author":"Zdilar","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.ncl.2015.08.006_bib230","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1200\/JCO.2000.18.11.2316","article-title":"Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions","volume":"18","author":"Trask","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ncl.2015.08.006_bib231","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/sj.mp.4000995","article-title":"Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy","volume":"7","author":"Capuron","year":"2002","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.ncl.2015.08.006_bib232","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/00004714-200202000-00014","article-title":"Increased depressive ratings in patients with hepatitis C receiving interferon-a\u2013based immunotherapy are related to interferon-a\u2013induced changes in the serotonergic system","volume":"22","author":"Bonaccorso","year":"2002","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.ncl.2015.08.006_bib233","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1176\/ajp.143.7.915","article-title":"Depression associated with ranitidine","volume":"143","author":"Billings","year":"1986","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.ncl.2015.08.006_bib234","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3109\/00048679109062644","article-title":"Ranitidine and depression","volume":"25","author":"Stocky","year":"1991","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.ncl.2015.08.006_bib235","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1212\/WNL.45.7.1277","article-title":"The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS\/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial","volume":"45","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2015.08.006_bib236","first-page":"221","article-title":"Interictal depression in patients with medically intractable complex partial seizures: electroencephalography and cerebral metabolic correlates","volume":"28","author":"Victoroff","year":"1990","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ncl.2015.08.006_bib237","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/0269881106063134","article-title":"Methylphenidate for \u03b1-interferon induced depression","volume":"20","author":"Camacho","year":"2006","journal-title":"J\u00a0Psychopharmacol"},{"key":"10.1016\/j.ncl.2015.08.006_bib238","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1345\/aph.1H133","article-title":"Venlafaxine for treatment of interferon alfa-induced depression","volume":"40","author":"Malek-Ahmadi","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ncl.2015.08.006_bib239","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1053\/jhep.2002.32104","article-title":"Incidence of interferon alfa-induced depression inpatients with chronic hepatitis C","volume":"35","author":"Zigante","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.ncl.2015.08.006_bib240","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1001\/jama.289.9.1107","article-title":"Incidence and preventability of adverse drug events among older persons in the ambulatory setting","volume":"289","author":"Gurwitz","year":"2003","journal-title":"JAMA"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073386191500081X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073386191500081X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T17:22:34Z","timestamp":1718212954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073386191500081X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":240,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S073386191500081X"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2015.08.006","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medicinal-Induced Behavior Disorders","name":"articletitle","label":"Article Title"},{"value":"Neurologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncl.2015.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}